Literature DB >> 34064104

Dysregulation of Pulmonary Responses in Severe COVID-19.

Dandan Wu1,2, Xuexian O Yang1.   

Abstract

Patients with coronavirus disease 2019 (COVID-19) predominantly have a respiratory tract infection with various symptoms and high mortality is associated with respiratory failure second to severe disease. The risk factors leading to severe disease remain unclear. Here, we reanalyzed a published single-cell RNA-Seq (scRNA-Seq) dataset and found that bronchoalveolar lavage fluid (BALF) of patients with severe disease compared to those with mild disease contained decreased TH17-type cells, decreased IFNA1-expressing cells with lower expression of toll-like receptor 7 (TLR7) and TLR8, increased IgA-expressing B cells, and increased hyperactive epithelial cells (and/or macrophages) expressing matrix metalloproteinases (MMPs), hyaluronan synthase 2 (HAS2), and plasminogen activator inhibitor-1 (PAI-1), which may together contribute to the pulmonary pathology in severe COVID-19. We propose IFN-I (and TLR7/TLR8) and PAI-1 as potential biomarkers to predict the susceptibility to severe COVID-19.

Entities:  

Keywords:  COVID-19; IgA; PAI-1; TH17; type I interferon

Mesh:

Substances:

Year:  2021        PMID: 34064104     DOI: 10.3390/v13060957

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  40 in total

1.  SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.

Authors:  Julian Braun; Lucie Loyal; Marco Frentsch; Daniel Wendisch; Philipp Georg; Florian Kurth; Stefan Hippenstiel; Manuela Dingeldey; Beate Kruse; Florent Fauchere; Emre Baysal; Maike Mangold; Larissa Henze; Roland Lauster; Marcus A Mall; Kirsten Beyer; Jobst Röhmel; Sebastian Voigt; Jürgen Schmitz; Stefan Miltenyi; Ilja Demuth; Marcel A Müller; Andreas Hocke; Martin Witzenrath; Norbert Suttorp; Florian Kern; Ulf Reimer; Holger Wenschuh; Christian Drosten; Victor M Corman; Claudia Giesecke-Thiel; Leif Erik Sander; Andreas Thiel
Journal:  Nature       Date:  2020-07-29       Impact factor: 49.962

2.  Association between capacity of interferon-alpha production and metabolic parameters.

Authors:  Masumi Tominaga; Kazuko Uno; Katsumi Yagi; Michiaki Fukui; Goji Hasegawa; Toshikazu Yoshikawa; Naoto Nakamura; Naoto Nakumura
Journal:  J Interferon Cytokine Res       Date:  2010-06       Impact factor: 2.607

3.  Plasminogen activator and plasminogen activator inhibitor activities in a reference population.

Authors:  C Krishnamurti; D B Tang; C F Barr; B M Alving
Journal:  Am J Clin Pathol       Date:  1988-06       Impact factor: 2.493

4.  Loss of T-bet confers survival advantage to influenza-bacterial superinfection.

Authors:  Jun Zhi Er; Ricky Abdi Gunawan Koean; Jeak Ling Ding
Journal:  EMBO J       Date:  2018-10-15       Impact factor: 11.598

5.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Authors:  Qiurong Ruan; Kun Yang; Wenxia Wang; Lingyu Jiang; Jianxin Song
Journal:  Intensive Care Med       Date:  2020-03-03       Impact factor: 17.440

6.  Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies.

Authors:  Darrell O Ricke
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

7.  COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas.

Authors:  Xianwen Ren; Wen Wen; Xiaoying Fan; Wenhong Hou; Bin Su; Pengfei Cai; Jiesheng Li; Yang Liu; Fei Tang; Fan Zhang; Yu Yang; Jiangping He; Wenji Ma; Jingjing He; Pingping Wang; Qiqi Cao; Fangjin Chen; Yuqing Chen; Xuelian Cheng; Guohong Deng; Xilong Deng; Wenyu Ding; Yingmei Feng; Rui Gan; Chuang Guo; Weiqiang Guo; Shuai He; Chen Jiang; Juanran Liang; Yi-Min Li; Jun Lin; Yun Ling; Haofei Liu; Jianwei Liu; Nianping Liu; Shu-Qiang Liu; Meng Luo; Qiang Ma; Qibing Song; Wujianan Sun; GaoXiang Wang; Feng Wang; Ying Wang; Xiaofeng Wen; Qian Wu; Gang Xu; Xiaowei Xie; Xinxin Xiong; Xudong Xing; Hao Xu; Chonghai Yin; Dongdong Yu; Kezhuo Yu; Jin Yuan; Biao Zhang; Peipei Zhang; Tong Zhang; Jincun Zhao; Peidong Zhao; Jianfeng Zhou; Wei Zhou; Sujuan Zhong; Xiaosong Zhong; Shuye Zhang; Lin Zhu; Ping Zhu; Bin Zou; Jiahua Zou; Zengtao Zuo; Fan Bai; Xi Huang; Penghui Zhou; Qinghua Jiang; Zhiwei Huang; Jin-Xin Bei; Lai Wei; Xiu-Wu Bian; Xindong Liu; Tao Cheng; Xiangpan Li; Pingsen Zhao; Fu-Sheng Wang; Hongyang Wang; Bing Su; Zheng Zhang; Kun Qu; Xiaoqun Wang; Jiekai Chen; Ronghua Jin; Zemin Zhang
Journal:  Cell       Date:  2021-02-03       Impact factor: 41.582

8.  Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.

Authors:  Jonas Schulte-Schrepping; Nico Reusch; Daniela Paclik; Kevin Baßler; Stephan Schlickeiser; Bowen Zhang; Benjamin Krämer; Tobias Krammer; Sophia Brumhard; Lorenzo Bonaguro; Elena De Domenico; Daniel Wendisch; Martin Grasshoff; Theodore S Kapellos; Michael Beckstette; Tal Pecht; Adem Saglam; Oliver Dietrich; Henrik E Mei; Axel R Schulz; Claudia Conrad; Désirée Kunkel; Ehsan Vafadarnejad; Cheng-Jian Xu; Arik Horne; Miriam Herbert; Anna Drews; Charlotte Thibeault; Moritz Pfeiffer; Stefan Hippenstiel; Andreas Hocke; Holger Müller-Redetzky; Katrin-Moira Heim; Felix Machleidt; Alexander Uhrig; Laure Bosquillon de Jarcy; Linda Jürgens; Miriam Stegemann; Christoph R Glösenkamp; Hans-Dieter Volk; Christine Goffinet; Markus Landthaler; Emanuel Wyler; Philipp Georg; Maria Schneider; Chantip Dang-Heine; Nick Neuwinger; Kai Kappert; Rudolf Tauber; Victor Corman; Jan Raabe; Kim Melanie Kaiser; Michael To Vinh; Gereon Rieke; Christian Meisel; Thomas Ulas; Matthias Becker; Robert Geffers; Martin Witzenrath; Christian Drosten; Norbert Suttorp; Christof von Kalle; Florian Kurth; Kristian Händler; Joachim L Schultze; Anna C Aschenbrenner; Yang Li; Jacob Nattermann; Birgit Sawitzki; Antoine-Emmanuel Saliba; Leif Erik Sander
Journal:  Cell       Date:  2020-08-05       Impact factor: 41.582

9.  Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.

Authors:  Xiangyu Chen; Zhiwei Pan; Shuai Yue; Fei Yu; Junsong Zhang; Yang Yang; Ren Li; Bingfeng Liu; Xiaofan Yang; Leiqiong Gao; Zhirong Li; Yao Lin; Qizhao Huang; Lifan Xu; Jianfang Tang; Li Hu; Jing Zhao; Pinghuang Liu; Guozhong Zhang; Yaokai Chen; Kai Deng; Lilin Ye
Journal:  Signal Transduct Target Ther       Date:  2020-09-02

10.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.

Authors:  Kevin W Ng; Nikhil Faulkner; Georgina H Cornish; Annachiara Rosa; Ruth Harvey; Saira Hussain; Rachel Ulferts; Christopher Earl; Antoni G Wrobel; Donald J Benton; Chloe Roustan; William Bolland; Rachael Thompson; Ana Agua-Doce; Philip Hobson; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine F Houlihan; Kirsty Thomson; Emilie Sanchez; Gee Yen Shin; Moira J Spyer; Dhira Joshi; Nicola O'Reilly; Philip A Walker; Svend Kjaer; Andrew Riddell; Catherine Moore; Bethany R Jebson; Meredyth Wilkinson; Lucy R Marshall; Elizabeth C Rosser; Anna Radziszewska; Hannah Peckham; Coziana Ciurtin; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve J Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis
Journal:  Science       Date:  2020-11-06       Impact factor: 47.728

View more
  8 in total

1.  Matrix Metalloproteinases on Severe COVID-19 Lung Disease Pathogenesis: Cooperative Actions of MMP-8/MMP-2 Axis on Immune Response through HLA-G Shedding and Oxidative Stress.

Authors:  Pedro V da Silva-Neto; Valéria B do Valle; Carlos A Fuzo; Talita M Fernandes; Diana M Toro; Thais F C Fraga-Silva; Patrícia A Basile; Jonatan C S de Carvalho; Vinícius E Pimentel; Malena M Pérez; Camilla N S Oliveira; Lilian C Rodrigues; Victor A F Bastos; Sandra O C Tella; Ronaldo B Martins; Augusto M Degiovani; Fátima M Ostini; Marley R Feitosa; Rogerio S Parra; Fernando C Vilar; Gilberto G Gaspar; José J R da Rocha; Omar Feres; Eurico Arruda; Sandra R Maruyama; Elisa M S Russo; Angelina L Viana; Isabel K F M Santos; Vânia L D Bonato; Cristina R B Cardoso; Jose E Tanus-Santos; Eduardo A Donadi; Lucia H Faccioli; Marcelo Dias-Baruffi; Ana P M Fernandes; Raquel F Gerlach; Carlos A Sorgi
Journal:  Biomolecules       Date:  2022-04-19

Review 2.  The unfavorable clinical outcome of COVID-19 in smokers is mediated by H3K4me3, H3K9me3 and H3K27me3 histone marks.

Authors:  Milad Shirvaliloo
Journal:  Epigenomics       Date:  2022-01-13       Impact factor: 4.778

3.  Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection.

Authors:  Wolfgang Bauer; Marcus Weber; Eva Diehl-Wiesenecker; Noa Galtung; Monika Prpic; Rajan Somasundaram; Rudolf Tauber; Jochen M Schwenk; Patrick Micke; Kai Kappert
Journal:  Viruses       Date:  2021-12-07       Impact factor: 5.048

Review 4.  Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19.

Authors:  Toshifumi Matsuyama; Steven K Yoshinaga; Kimitaka Shibue; Tak W Mak
Journal:  Cell Death Differ       Date:  2021-10-18       Impact factor: 15.828

Review 5.  Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes.

Authors:  Jacopo Sabbatinelli; Giulia Matacchione; Angelica Giuliani; Deborah Ramini; Maria Rita Rippo; Antonio Domenico Procopio; Massimiliano Bonafè; Fabiola Olivieri
Journal:  Mech Ageing Dev       Date:  2022-03-25       Impact factor: 5.498

Review 6.  Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19.

Authors:  Caspar I van der Made; Mihai G Netea; Frank L van der Veerdonk; Alexander Hoischen
Journal:  Genome Med       Date:  2022-08-19       Impact factor: 15.266

Review 7.  Frontline workers: Mediators of mucosal immunity in community acquired pneumonia and COVID-19.

Authors:  Priyanka S Hastak; Christopher R Andersen; Anthony D Kelleher; Sarah C Sasson
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

8.  Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia.

Authors:  Marina Mantzourani; George P Chrousos; Styliani A Geronikolou; Işil Takan; Athanasia Pavlopoulou
Journal:  Int J Mol Med       Date:  2022-01-21       Impact factor: 4.101

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.